Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Water soluble, optically active monofunctional Pd(ii) and Pt(ii) compounds: promising adhesive and antimigratory effects on human prostate PC-3 cancer cells.

de la Cueva-Alique I, Muñoz-Moreno L, de la Torre-Rubio E, Bajo AM, Gude L, Cuenca T, Royo E.

Dalton Trans. 2019 Sep 4. doi: 10.1039/c9dt02873k. [Epub ahead of print]

PMID:
31482936
2.

Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.

Muñoz-Moreno L, Carmena MJ, Schally AV, Prieto JC, Bajo AM.

Invest New Drugs. 2019 Jul 17. doi: 10.1007/s10637-019-00831-2. [Epub ahead of print]

PMID:
31312936
3.

Insight into the antitumor activity of carbosilane Cu(ii)-metallodendrimers through their interaction with biological membrane models.

Sanz Del Olmo N, Carloni R, Bajo AM, Ortega P, Fattori A, Gómez R, Ottaviani MF, García-Gallego S, Cangiotti M, de la Mata FJ.

Nanoscale. 2019 Jul 28;11(28):13330-13342. doi: 10.1039/c9nr03313k. Epub 2019 Jul 4.

PMID:
31271405
4.

Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.

Muñoz-Moreno L, Schally AV, Prieto JC, Carmena MJ, Bajo AM.

Prostate. 2018 Sep;78(12):915-926. doi: 10.1002/pros.23648. Epub 2018 May 10.

PMID:
29748961
5.

Biological evaluation of water soluble arene Ru(II) enantiomers with amino-oxime ligands.

de la Cueva-Alique I, Sierra S, Muñoz-Moreno L, Pérez-Redondo A, Bajo AM, Marzo I, Gude L, Cuenca T, Royo E.

J Inorg Biochem. 2018 Jun;183:32-42. doi: 10.1016/j.jinorgbio.2018.02.018. Epub 2018 Mar 6.

PMID:
29529470
6.

Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.

Muñoz-Moreno L, Bajo AM, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2017 May 5;446:59-69. doi: 10.1016/j.mce.2017.02.011. Epub 2017 Feb 11.

PMID:
28193499
7.

Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.

Vacas E, Muñoz-Moreno L, Valenzuela PL, Prieto JC, Schally AV, Carmena MJ, Bajo AM.

Peptides. 2016 Dec;86:153-161. doi: 10.1016/j.peptides.2016.11.004. Epub 2016 Nov 2.

PMID:
27816751
8.

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.

Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.

Oncotarget. 2016 Aug 9;7(32):52195-52206. doi: 10.18632/oncotarget.10710.

9.

Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands.

Benabdelouahab Y, Muñoz-Moreno L, Frik M, de la Cueva-Alique I, El Amrani MA, Contel M, Bajo AM, Cuenca T, Royo E.

Eur J Inorg Chem. 2015 May;2015(13):2295-2307. Epub 2015 Apr 9.

10.

Novel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents.

de la Cueva-Alique I, Muñoz-Moreno L, Benabdelouahab Y, Elie BT, El Amrani MA, Mosquera ME, Contel M, Bajo AM, Cuenca T, Royo E.

J Inorg Biochem. 2016 Mar;156:22-34. doi: 10.1016/j.jinorgbio.2015.12.002. Epub 2015 Dec 9.

11.

VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.

Fernández-Martínez AB, Carmena MJ, Bajo AM, Vacas E, Sánchez-Chapado M, Prieto JC.

Cell Signal. 2015 Feb;27(2):236-44. doi: 10.1016/j.cellsig.2014.11.005. Epub 2014 Nov 15.

PMID:
25446255
12.

Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.

Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Prieto JC, Bajo AM.

Invest New Drugs. 2014 Oct;32(5):871-82. doi: 10.1007/s10637-014-0131-4. Epub 2014 Jul 8.

PMID:
25000999
13.

Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.

Vacas E, Muñoz-Moreno L, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Int J Biochem Cell Biol. 2014 Aug;53:295-301. doi: 10.1016/j.biocel.2014.05.036. Epub 2014 Jun 4.

PMID:
24905957
14.

Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice.

Vacas E, Arenas MI, Muñoz-Moreno L, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Cancer Lett. 2013 Aug 9;336(1):196-203. doi: 10.1016/j.canlet.2013.04.033. Epub 2013 May 7.

PMID:
23664888
15.

Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma.

Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2013 Jan 30;365(2):212-22. doi: 10.1016/j.mce.2012.10.021. Epub 2012 Nov 1.

PMID:
23123564
16.

Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells.

Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Peptides. 2012 Dec;38(2):275-81. doi: 10.1016/j.peptides.2012.09.011. Epub 2012 Sep 19.

PMID:
23000305
17.

Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.

Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.

Int J Cancer. 2013 Feb 15;132(4):755-65. doi: 10.1002/ijc.27716. Epub 2012 Jul 27.

18.

Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.

Fernández-Martínez AB, Carmena MJ, Arenas MI, Bajo AM, Prieto JC, Sánchez-Chapado M.

Histol Histopathol. 2012 Aug;27(8):1093-101. doi: 10.14670/HH-27.1093.

PMID:
22763881
19.

Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.

Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC, Carmena MJ.

Biochim Biophys Acta. 2012 Oct;1823(10):1676-85. doi: 10.1016/j.bbamcr.2012.06.018. Epub 2012 Jun 21.

20.

RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Bajo AM, Prieto JC.

Mol Cell Endocrinol. 2012 Jan 2;348(1):241-6. doi: 10.1016/j.mce.2011.08.031. Epub 2011 Aug 27.

PMID:
21896307
21.

Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.

Fernández-Martínez AB, Bajo AM, Isabel Arenas M, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Cancer Lett. 2010 Dec 18;299(1):11-21. doi: 10.1016/j.canlet.2010.07.019. Epub 2010 Aug 14.

PMID:
20709445
22.

Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.

Valdehita A, Bajo AM, Fernández-Martínez AB, Arenas MI, Vacas E, Valenzuela P, Ruíz-Villaespesa A, Prieto JC, Carmena MJ.

Peptides. 2010 Nov;31(11):2035-45. doi: 10.1016/j.peptides.2010.07.024. Epub 2010 Aug 5.

PMID:
20691743
23.

Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).

Sotomayor S, Muñoz-Moreno L, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.

Int J Cancer. 2010 Oct 15;127(8):1813-22. doi: 10.1002/ijc.25192.

24.

Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.

Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC.

Peptides. 2009 Dec;30(12):2357-64. doi: 10.1016/j.peptides.2009.09.018. Epub 2009 Sep 20.

PMID:
19772879
25.

Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.

Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Prostate. 2009 May 15;69(7):774-86. doi: 10.1002/pros.20930.

PMID:
19189304
26.

Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.

Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, Prieto JC.

Mol Cell Endocrinol. 2009 Apr 10;302(1):41-8. doi: 10.1016/j.mce.2008.11.024. Epub 2008 Dec 3.

PMID:
19101605
27.

Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.

Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.

Int J Oncol. 2007 Nov;31(5):1223-30.

PMID:
17912451
28.

Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM.

Regul Pept. 2007 Dec 4;144(1-3):101-8. Epub 2007 Jun 28.

PMID:
17683807
29.

Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.

Collado B, Carmena MJ, Clemente C, Prieto JC, Bajo AM.

Peptides. 2007 Sep;28(9):1896-901. Epub 2007 May 3.

PMID:
17544169
30.

Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.

Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2007 May 30;270(1-2):8-16. Epub 2007 Jan 21.

PMID:
17434257
31.

Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.

Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC.

Int J Oncol. 2005 Jun;26(6):1629-35.

PMID:
15870879
32.

Association of adenylate cyclase with an actin-like protein in the human myometrium.

Bajo AM, Prieto JC, Valenzuela P, Martínez P, Menor C, Marina A, Vázquez J, Guijarro LG.

Gynecol Endocrinol. 2004 Feb;18(2):89-96.

PMID:
15195500
33.

Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.

Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4996-5001. Epub 2004 Mar 24.

34.

Solubilization of adenylyl cyclase from human myometrium in a alphas-coupled form.

Bajo AM, Prieto JC, Valenzuela P, Martinez P, Guijarro LG.

Biosci Rep. 2003 Aug;23(4):175-86.

PMID:
14748538
35.

Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.

Bajo AM, Schally AV, Groot K, Szepeshazi K.

Br J Cancer. 2004 Jan 12;90(1):245-52.

36.

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.

Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G.

Cancer. 2003 Oct 1;98(7):1401-10.

38.

Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.

Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A.

Int J Oncol. 2003 May;22(5):1141-6.

PMID:
12684683
39.

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Letsch M, Schally AV, Busto R, Bajo AM, Varga JL.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1250-5. Epub 2003 Jan 21.

40.
41.

Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A.

Anticancer Drugs. 2002 Oct;13(9):949-56.

PMID:
12394258
42.

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

Szereday Z, Schally AV, Nagy A, Plonowski A, Bajo AM, Halmos G, Szepeshazi K, Groot K.

Br J Cancer. 2002 Apr 22;86(8):1322-7.

43.

Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.

Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3836-41. Epub 2002 Mar 12.

44.

Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.

Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Bajo AM.

J Cancer Res Clin Oncol. 2001 Nov;127(11):645-52.

PMID:
11710593
45.

Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.

Arencibia JM, Schally AV, Krupa M, Bajo AM, Nagy A, Szepeshazi K, Plonowski A.

Int J Oncol. 2001 Sep;19(3):571-7.

PMID:
11494038
46.

Expression of vasoactive intestinal peptide (VIP) receptors in human uterus.

Bajo AM, Juarranz MG, Valenzuela P, Martínez P, Prieto JC, Guijarro LG.

Peptides. 2000 Sep;21(9):1383-8.

PMID:
11072126
47.

Ontogeny of vasoactive intestinal peptide receptors in rat ventral prostate.

Juarranz MG, Guijarro LG, Bajo AM, Carmena MJ, Prieto JC.

Gen Pharmacol. 1994 May;25(3):509-14.

PMID:
7926599
48.

Analysis of vasoactive intestinal peptide receptors and the G protein regulation of adenylyl cyclase in seminal vesicle membranes from streptozotocin-diabetic rats.

Rodriguez-Pena MS, Guijarro LG, Juarranz MG, Rodriguez-Henche N, Bajo AM, Aguado F, Prieto JC.

Cell Signal. 1994 Feb;6(2):147-56.

PMID:
8086277
49.

VIP receptor/effector system in liver membranes from cholestatic rats.

Rodriguez-Henche N, Guijarro LG, Bajo AM, Arilla E, Prieto JC.

Peptides. 1994;15(2):353-7.

PMID:
8008639
50.

Stimulation of the adenylyl cyclase activity in human endometrial membranes by VIP and related peptides.

Bajo AM, Guijarro LG, Juarranz MG, Valenzuela P, Martinez P, Prieto JC.

Biosci Rep. 1993 Apr;13(2):69-77.

PMID:
8397008

Supplemental Content

Support Center